Table 2.
Adverse effects of treatment experienced by patients included in the study
| Adverse effect | group T (n = 18) |
group N (n = 17) |
p |
|---|---|---|---|
| Arthralgia | 7 (38.9%) | 1 (5.9%) | 0.041 |
| Myalgia | 3 (16.7%) | 1 (5.9%) | 0.603 |
| Persistent breakthrough bleeding | 0 (0.0%) | 2 (11.8%) | 0.229 |
| Depression | 4 (22.2%) | 1 (5.9%) | 0.338 |
| Insomnia | 3 (16.7%) | 0 (0.0%) | 0.229 |
| Decreased libido | 4 (22.2%) | 2 (11.8%) | 0.658 |
| Vaginal dryness | 3 (16.7%) | 0 (0.0%) | 0.229 |
| Hot flushes | 4 (22.2%) | 0 (0.0%) | 0.104 |
| Hair loss | 2 (11.1%) | 0 (0.0%) | 0.486 |
| Headache | 2 (11.1%) | 0 (0.0%) | 0.486 |
| Weight gain | 1 (5.6%) | 2 (11.8%) | 0.603 |
| At least one adverse effect | 14 (77.8%) | 6 (35.3%) | 0.018 |